Medicaid Pharmacy and Therapeutics Committee

New York State Office Of Medicaid Management
Pharmacy and Therapeutics Committee - Agenda for September 19, 2006

The Pharmacy & Therapeutics Committee will meet Tuesday, September 19, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items:

1. Identification of preferred drugs in the therapeutic class Inhaled Beta2 Adrenergic Agents - Short Acting

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Accuneb (albuterol), albuterol, albuterol HFA, Alupent (metaproterenol), Maxair Autohaler (pirbuterol), metaproterenol, Proventil (albuterol), Proventil HFA (albuterol), Ventolin HFA (albuterol), Xopenex (levalbuterol), Xopenex HFA (levalbuterol)

2. Identification of preferred drugs in the therapeutic class Inhaled Beta2 Adrenergic Agents - Long Acting

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Foradil (formoterol), Serevent Diskus (salmeterol)

3. Identification of preferred drugs in the therapeutic class Inhaled Anticholinergics

  • Description: The Committee will review the following drugs and combination products to determine preferred and non-preferred status.

    Drug(s) Affected: Atrovent (ipratropium), Atrovent HFA (ipratropium), Combivent (ipratropium/albuterol), Duoneb (ipratropium/albuterol), ipratropium, Spiriva (tiotropium)

4. Identification of preferred drugs in the therapeutic class Inhaled Corticosteroids

  • Description: The Committee will review the following drugs and combination products to determine preferred and non-preferred status.

    Drug(s) Affected: Advair Diskus (fluticasone/salmeterol), Aerobid/Aerobid-M (flunisolide), Asmanex (mometasone), Azmacort (triamcinolone), Flovent HFA (fluticasone), Pulmicort (budesonide), Qvar (beclomethasone)

5. Identification of preferred drugs in the therapeutic class Phosphate Binders/Regulators

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Fosrenol (lanthanum), Phoslo (calcium acetate), Renagel (sevelamer)

6. Identification of preferred drugs in the therapeutic class Topical Immunomodulators

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Elidel (pimecrolimus), Protopic (tacrolimus)

AGENDA

TimeAgenda
 8:45 - 9:00 Welcome and Introductions
 9:00 - 10:00 Comments from interested parties*
10:00 - 10:30 Clinical Review of Inhaled Beta2 Adrenergic Agents - Short Acting
10:30 - 11:00 Clinical Review of Inhaled Beta2 Adrenergic Agents - Long Acting
11:00 - 11:30 Clinical Review of Inhaled Anticholinergics
11:30 - 12:30 Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
12:30 - 12:45 Final Recommendations for preferred drugs (Inhaled Beta2 Adrenergic Agents - Short and Long Acting, Inhaled Anticholinergics)
12:45 - 1:15  Clinical Review of Inhaled Corticosteroids
 1:15 - 1:45  Clinical Review of Phosphate Binders/Regulators
 1:45 - 2:15  Clinical Review of Topical Immunomodulators
 2:15 - 2:45 Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
 2:45 - 2:50 Final Recommendations (Inhaled Corticosteroids, Phosphate Binders/Regulators, Topical Immunomodulators)
 2:50 - 3:00  DOH Update, Final Comments and Adjournment

*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit clinical information such as a clinical study, a clinical report, or a clinical executive summary, must submit these documents at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.

Posted August 18, 2006